HLA-A2 status influence the outcomes in Non small cell lung cancer patients treated with Nivolumab,Pembrolizumab or Atezolizumab

Trial Profile

HLA-A2 status influence the outcomes in Non small cell lung cancer patients treated with Nivolumab,Pembrolizumab or Atezolizumab

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2016 New trial record
    • 11 Oct 2016 Preliminary results presented at the 41st European Society for Medical Oncology Congress (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top